Award type :
Product Development Award
Product Development Award
Product type :
Vaccines
Vaccines
Award year :
2020
2020
Project start date :
07 / 31 / 2020
07 / 31 / 2020
Project end date :
06 / 30 /2021
06 / 30 /2021
Project duration (months) :
12
12
Development stage :
Preclinical
Preclinical
Target disease :
COVID-19
COVID-19
Region served :
World
World
Recipient organization / Country of funding recipient organization :
SK Bioscience / Republic of Korea
SK Bioscience / Republic of Korea
Collaborator(s) / Country :
Catholic University of Korea / Republic of Korea, Eubiologics / Republic of Korea, CTCVac / Republic of Korea
Catholic University of Korea / Republic of Korea, Eubiologics / Republic of Korea, CTCVac / Republic of Korea
Funding amount(KRW) :
500,000,000
500,000,000
This project has the potential to develop a novel viral vector platform for rapid response to future outbreaks. SK Bioscience will manufacture the recombinant viral vector expressing COVID-19 antigen, while Catholic University of Korea will develop the animal model and evaluate its efficacy.